Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023)

Zentalis Pharmaceuticals has reported Deferred Taxes over the past 2 years, most recently at -$756000.0 for Q2 2023.

  • Quarterly results put Deferred Taxes at -$756000.0 for Q2 2023, down 1121.62% from a year ago — trailing twelve months through Mar 2024 was -$756000.0 (up 4.55% YoY), and the annual figure for FY2023 was -$853000.0, down 10.92%.
  • Deferred Taxes for Q2 2023 was -$756000.0 at Zentalis Pharmaceuticals, down from -$97000.0 in the prior quarter.
  • Over the last five years, Deferred Taxes for ZNTL hit a ceiling of $74000.0 in Q2 2022 and a floor of -$769000.0 in Q4 2022.